The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

PARIS, France I February 12, 2025 I GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...

In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...